Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy

Scandinavian Journal of Immunology

Volumn 63, Issue 6, 2006, Pages 478-486

  Ostrowski, S R ^a   Katzenstein, T L ^a   Pedersen, M ^a   Hoyer Hansen G ^b   Gerstoft, J ^a   Pedersen, B K ^a   Ullum, H ^a  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UROKINASE RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOWN-REGULATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYDROLYSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN ISOFORMS; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SOLUBILITY;

EID: 33745521267     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.001768.x     Document Type: Article

References (71)

1. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:337-42.
2. Cinque P, Nebuloni M, Santovito ML et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol 2004;55:687-94.
3. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:23-31.
4. Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000;96:4091-5.
5. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003;9:1499-528.
6. Nykjaer A, Moller B, Todd RF et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 1994;152:505-16.
7. Nykjaer A, Petersen CM, Moller B, Andreasen PA, Gliemann J. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells. FEBS Lett 1992;300:13-7.
8. Plesner T, Ralfkiaer E, Wittrup M et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994;102:835-41.
9. Haddock RC, Spell ML, Baker CD III et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem 1991;266:21466-73.
10. Hoyer-Hansen G, Ronne E, Solberg H et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992;267:18224-9.
11. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991;266:1926-33.
12. Wilhelm OG, Wilhelm S, Escott GM et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 1999;180:225-35.
13. De Witte H, Sweep F, Brunner N et al. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer 1998;77:236-42.
14. Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 2000;475:52-6.
15. Mustjoki S, Sidenius N, Sier CF et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000;60:7126-32.
16. Riisbro R, Christensen IJ, Piironen T et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002;8:1132-41.
17. Riisbro R, Piironen T, Brünner N et al. Meassurements of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay 2002;25:53-6.
18. Piironen T, Laursen B, Paas J et al. Specific immunoassays for detection intact cleaved forms urokinase receptor. Clin Chem 2004;50:2059-68.
19. Katzenstein TL, Ullum H, Roge BT et al. Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months. HIV Med 2003;4:53-61.
20. Ploug M, Ostergaard S, Gardsvoll H et al. Peptide-derived antagonists of the urokinase receptor, affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001;40:12157-68.
21. Leutscher PDC, Pedersen M, Raharisolo C et al. Increased prevalence of leukocytes and elevated cytokine levels in semen from Schistosoma haematobium-infected individuals. J Infect Dis 2005;191:1639-47.
22. Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997;243:21-6.
23. Hoyer-Hansen G, Pessara U, Holm A et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 2001;358:673-9.
24. Speth C, Pichler I, Stockl G, Mair M, Dierich MP. Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection. Immunobiology 1998;199:152-62.
25. Frank I, Stoiber H, Godar S et al. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996;10:1611-20.
26. Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients. Scand J Immunol 2005;61:347-56.
27. Sier CF, Nicoletti I, Santovito ML et al. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 2004;91:403-11.
28. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
29. Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis Proteolysis 1998;12:191-204.
30. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 2005;93:192-8.
31. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998;91:2305-12.
32. Mustjoki S, Sidenius N, Vaheri A. Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells. FEBS Lett 2000;486:237-42.
33. Holst-Hansen C, Hamers MJ, Johannessen BE, Brunner N, Stephens RW. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer 1999;81:203-11.
34. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 1997;77:540-7.
35. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995;86:203-11.
36. Florquin S, van den Berg JG, Olszyna DP et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001;59:2054-61.
37. Wittenhagen P, Kronborg G, Weis N et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004;10:409-15.
38. Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002;6:686-92.
39. Ostrowski SR, Ullum H, Goka BQ et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005;191:1331-441.
40. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999;58:488-92.
41. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004;24:13-39.
42. Blasi F, Carmeliet P. uPAR a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
43. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004;25:450-5.
44. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 1998;188:1029-37.
45. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000;165:1513-9.
46. Gyetko MR, Sud S, Sonstein J, Polak T, Sud A, Curtis JL. Cutting edge: antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J Immunol 2001;167:5539-42.
47. Yoshida E, Tsuchiya K, Sugiki M, Sumi H, Mihara H, Maruyama M. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation 1996;20:319-26.
48. Sitrin RG, Todd RF III,, Mizukami IF, Gross TJ, Shollenberger SB, Gyetko MR. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 1994;84:1268-75.
49. Plesner T, Ploug M, Ellis V et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994;83:808-15.
50. Coleman JL, Gebbia JA, Benach JL. Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87). J Immunol 2001;166:473-80.
51. Chavakis T, Willuweit AK, Lupu F, Preissner KT, Kanse SM. Release of soluble urokinase receptor from vascular cells. Thromb Haemost 2001;86:686-93.
52. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-8.
53. Alonso K, Pontiggia P, Medenica R, Rizzo S. Cytokine patterns in adults with AIDS. Immunol Invest 1997;26:341-50.
54. Ullum H, Diamant M, Victor J et al. Increased circulating levels of interleukin-6 in HIV-seropositive subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:93-4.
55. Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression -down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol 1999;116:115-20.
56. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-40.
57. Ostrowski SR, Plomgaard P, Fischer CP et al. Interleukin-6 infusion during human endotoxemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol 2005;61:197-206.
58. Arno A, Ruiz L, Juan M et al. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. AIDS 1998;12:697-704.
59. Valdez H, Connick E, Smith KY et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16:1859-66.
60. Wei Y, Lukashev M. Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
61. Tarui T, Mazar AP, Cines DB, Takada Y. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001;276:3983-90.
62. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997;16:7279-86.
63. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15:1572-82.
64. Furlan F, Orlando S, Laudanna C et al. The soluble D2D3 (88-274): fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci 2004;117:2909-16.
65. Mizukami IF, Todd RF. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells. J Leukoc Biol 1998;64:203-13.
66. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994;337:131-4.
67. Kruger A, Soeltl R, Lutz V et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther 2000;7:292-9.
68. Lutz V, Reuning U, Kruger A et al. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001;382:789-98.
69. Handley MA, Steigbigel RT, Morrison SA. A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. J Virol 1996;70:4451-6.
70. Wada M, Wada NA, Shirono H, Taniguchi K, Tsuchie H, Koga J. Amino-terminal fragment of urokinase-type plasminogen activator inhibits hiv-1 replication. Biochem Biophys Res Commun 2001;284:346-51.
71. Alfano M, Sidenius N, Panzeri B, Blasi F, Poli G. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci USA 2002;99:8862-7.